Levin, Michael G. http://orcid.org/0000-0002-9937-9932
Nakao, Tetsushi http://orcid.org/0000-0001-9979-2682
Zekavat, Seyedeh M. http://orcid.org/0000-0003-4026-8944
Koyama, Satoshi http://orcid.org/0000-0002-9286-0360
Bick, Alexander G. http://orcid.org/0000-0001-5824-9595
Niroula, Abhishek
Ebert, Benjamin
Damrauer, Scott M. http://orcid.org/0000-0001-8009-1632
Natarajan, Pradeep http://orcid.org/0000-0001-8402-7435
Funding for this research was provided by:
National Institutes of Health (T32HL007843)
Article History
Received: 4 November 2021
Accepted: 25 March 2022
First Online: 4 May 2022
Competing interests
: PN reported receiving grants from Amgen, Apple, AstraZeneca, and Boston Scientific outside the submitted work; receiving personal fees from AstraZeneca, Blackstone Life Sciences, Novartis, Apple, Genentech/Roche, Foresite Labs; and having equity in and a spousal employment at Vertex Pharmaceuticals, all outside the present work. SMD reported receiving grants from the US Department of Veterans Affairs during the conduct of the study and receiving grants from RenalytixAI and personal fees from Calico Labs outside the submitted work. B.L.E. has received research funding from Celgene, Deerfield, Novartis, and Calico and consulting fees from GRAIL. He is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, TenSixteen Bio, Skyhawk Therapeutics, and Exo Therapeutics. All other authors have no conflicts to declare.